Discovery of an RNF126-Dependent Polθ Degrader Exhibiting In Vivo Activity in an HR-Deficient Tumor Model
DNA polymerase theta (Polθ), a multidomain DNA repair enzyme, has emerged as a promising synthetic-lethal target in homologous recombination (HR)-deficient tumors, yet current inhibitors directed at either its helicase or polymerase domain may not fully suppress the functions of the intact protein. Here, we report PR-6, a RNF126-dependent Polθ degrader identified through comparative degrader screening and structural optimization. In BRCA1-deficient MDA-MB-436 cells, PR-6 induced, concentration- and time-dependent Polθ degradation via an RNF126- and ubiquitin-proteasome-dependent mechanism. Compared with the Polθ helicase inhibitor AB25583 under the tested cellular conditions, PR-6 exhibited greater antiproliferative activity and induced more pronounced DNA damage and apoptosis. Moreover, PR-6 synergized with Olaparib in vitro and markedly potentiated its antitumor efficacy in an MDA-MB-436 xenograft model without overt toxicity. These findings support PR-6 as the first degrader probe for interrogating Polθ biology and provide proof of concept for Polθ degradation as a complementary strategy in HR-deficient tumors.
Authors
- Hua Xiang (ORCID: https://orcid.org/0000-0002-8937-4062)
- Guoshun Luo (ORCID: https://orcid.org/0000-0001-6279-2793)
- Maoxu Xiao
- Xinyan Liu (ORCID: https://orcid.org/0000-0001-9828-8660)
- Luyu Ma (ORCID: https://orcid.org/0000-0003-2907-8410)
- Mingjin Luo
- Xiaofan Ge
- Zhonglin Zhang
Institutions
- China Pharmaceutical University (CN)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1021/acs.jmedchem.6c02430
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province